Fixed-dose combination diuretics in congestive heart failure: an evaluation.
Thirty-two patients with congestive heart failure were studied for their clinical and biochemical responses to the administration of two combination diuretic products (hydrochlorothiazide/spironolactone and hydrochlorothiazide/triamterene) and the single entity diuretic furosemide. Data from these studies revealed the following: 1. Comparison of the patients on furosemide with those receiving the combination products showed no difference in serum potassium or 24-hour potassium excretion. 2. Significant changes in blood urea nitrogen, plasma renin activity, and urinary aldosterone excretion were noted with both fixed-combination medications but not with furosemide. 3. The combination diuretics offered no clinical benefits over the single agent furosemide. 4. Therapy is best served by the use of a single effective diuretic agent for the treatment of most patients with congestive heart failure.
D001806:Blood Urea Nitrogen; D004232:Diuretics / Q000008:administration & dosage* / Q000627:therapeutic use; D004338:Drug Combinations; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D006852:Hydrochlorothiazide / Q000627:therapeutic use; D012083:Renin / Q000097:blood; D013148:Spironolactone / Q000627:therapeutic use
D004232:Diuretics; D004338:Drug Combinations; D006852:Hydrochlorothiazide; D013148:Spironolactone; D012083:Renin